NANO-X IMAGING LTD (“Nanox” or the “Company,”
Nasdaq: NNOX), an innovative medical imaging technology
company, today announced that HealthCCSng, an AI-powered solution
created by Nanox’s deep-learning medical imaging analytics
subsidiary, Nanox.AI, was used in a clinical study evaluating
routine CT scans and found that 58% of patients unknowingly had
moderate to severe levels of coronary artery calcium (CAC), a
proven indicator of future cardiac events. The study was sponsored
by Nanox.AI and conducted by the Beilinson Hospital, one of the
largest and most renowned multidisciplinary medical institutions in
Israel, and utilized Nanox.AI’s HealthCCSng, an FDA-cleared and CE
marked tool designed specifically for cardiac health assessment.
Nanox.AI’s HealthCCSng solution utilizes medical imaging data
from routine chest CT scans to automatically quantify and analyze
CAC category. CAC is the strongest predictor of future cardiac
events, with patients in the highest category being over 20 times
more likely to suffer a cardiac event. Many studies show a clear
correlation between coronary artery calcium detected and severity
of disease.
“The patients in this study received routine CT scans that had
nothing to do with a cardiac concern. Nanox’s AI technology can
enable physicians to route these unsuspecting individuals with high
CAC levels to the appropriate care pathways and treatment,” said
Professor Ran Kornowski, Director of the Cardiology Center at
Beilinson Hospital, who lead the study with Prof. Ashraf Hamdan,
director of the Cardiovascular Imaging unit. “While the study’s
findings were staggering, we are encouraged by the important role
AI can play in early risk identification and prevention of cardiac
events.”
In the study, Nanox.Al’s HealthCCSng software was employed to
assess Coronary Artery Calcification (CAC) levels from non-gated,
non-contrast chest CT scans. The software’s categorizations were
subjected to qualitative evaluation by two radiologists who
reviewed each case. Patient categorization included low (CAC 0-99),
moderate (CAC 100-399), and severe (CAC > 400), with exclusions
applied to individuals with certain medical histories or
artifacts.
“We have integrated Nanox.AI’s HealthCCS solution within our
HMO-owned (Clalit) teaching hospital, and the outcomes have been
highly promising in terms of detecting previously undiagnosed
patients with elevated calcium levels from routine chest CT scans.
Even within our health-conscious population, we were able to
identify a significant number of individuals with hidden
cardiovascular disease and guide them onto the appropriate care
trajectory,” emphasized Prof. Ashraf Hamdan, Head of Cardiovascular
Imaging at Beilinson Hospital and chief investigator.
Among the 326 eligible patients who participated in the study
from January to July 2023, 101 out of 326 (31%) exhibited severe
CAC, 88 (27%) had moderate CAC, and 137 (42%) showed low CAC.
Patients with severe CAC levels were referred to specialized
preventive cardiology clinics for in-depth evaluation and
treatment. Those categorized with low and moderate CAC were
directed to primary care physicians for further assessment and
medical optimization.
“HealthCCSng’s ability to detect hidden cardiovascular risks
from routine CT scans offers a significant stride toward preventive
cardiac care,” said Dr. Orit Wimpfheimer, Chief Medical Officer of
Nanox.AI. “Given the global prominence of cardiovascular disease as
the leading cause of mortality and the fact that nearly half of
patients realize their condition only after an initial heart
attack, leveraging such technologies for general population
screening and early detection is absolutely imperative.”
Typically, CAC scoring may be attained on a cardiac-gated scan
which subjects patients to additional cost and radiation exposure
and is typically not covered by insurance companies. HealthCCSng
supports clinicians in diagnosing patients with cardiovascular
disease who were previously undetected, while stratifying such
patients so that they can obtain the appropriate preventative
cardiac care and treatment. As a result, patients can be placed on
relevant care pathways to prevent or mitigate the chance of a
future incident by detecting early signs of disease and estimating
the likelihood of future cardiovascular events.
Nanox.AI solutions are developed to target highly prevalent
chronic and acute diseases affecting large populations around the
world, helping clinicians extract valuable and actionable clinical
insights from medical imaging that might otherwise go unnoticed.
These incidental or “hidden” findings can potentially initiate
further medical assessment to determine whether patients may need
additional preventive care. Beyond HealthCCSng, Nanox.AI’s
portfolio includes an FDA-cleared imaging solution in bone health
(HealthOST) and one in development for fatty liver disease
(HealthFLD), which also use routine medical CT imaging to help
physicians identify early signs of diseases, such as osteoporosis
and non-alcoholic fatty liver disease. This enables further work-up
and possible treatment, helping prevent potentially major,
life-changing health events.
About Nanox Nano-X Imaging Ltd (Nasdaq:
NNOX) is focused on applying its proprietary medical imaging
technology and solutions to make diagnostic medicine more
accessible and affordable across the globe. The vision of Nanox is
to increase the early detection of medical conditions that are
discoverable by medical imaging technologies based on X-ray, by
improving access to imaging, reducing imaging costs and enhancing
imaging efficiency, which Nanox believes is key to increasing early
prevention and treatment, improving health outcomes, and,
ultimately, saving lives. Nanox is developing a holistic imaging
solution, which includes the Nanox System, comprised of Nanox.ARC
using its novel MEMs X-ray source technology and Nanox.CLOUD, a
companion cloud software, integrated with AI solutions and
teleradiology services. For more information, please visit
www.nanox.vision.
About Nanox.AI Nanox.AI is
the deep-learning medical imaging analytics subsidiary of Nanox.
Nanox.AI solutions are developed to target highly prevalent chronic
and acute diseases affecting large populations around the world.
Leveraging AI, Nanox.AI helps clinicians extract valuable and
actionable clinical insights from routine medical imaging that
otherwise may go unnoticed, potentially initiating further medical
assessment to establish individual preventative care pathways for
patients. For more information, please visit
www.nanox.vision/ai.
Forward-Looking Statements This press
release may contain forward-looking statements that are subject to
risks and uncertainties. All statements that are not historical
facts contained in this press release are forward-looking
statements. Such statements include, but are not limited to, any
statements relating to the initiation, timing, progress and results
of the Company’s research and development, manufacturing, and
commercialization activities with respect to its X-ray source
technology and the Nanox.ARC, the ability to realize the expected
benefits of its recent acquisitions and the projected business
prospects of the Company and the acquired companies. In some cases,
you can identify forward-looking statements by terminology such as
“can,” “might,” “believe,” “may,” “estimate,” “continue,”
“anticipate,” “intend,” “should,” “plan,” “should,” “could,”
“expect,” “predict,” “potential,” or the negative of these terms or
other similar expressions. Forward-looking statements are based on
information the Company has when those statements are made or
management’s good faith belief as of that time with respect to
future events and are subject to risks and uncertainties that could
cause actual performance or results to differ materially from those
expressed in or suggested by the forward-looking statements.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks related to (i) Nanox’s
ability to complete development of the Nanox System; (ii) Nanox’s
ability to successfully demonstrate the feasibility of its
technology for commercial applications; (iii) Nanox’s expectations
regarding the necessity of, timing of filing for, and receipt and
maintenance of, regulatory clearances or approvals regarding its
technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies
worldwide and its ongoing compliance with applicable quality
standards and regulatory requirements; (iv) Nanox’s ability to
realize the anticipated benefits of the recent acquisitions, which
may be affected by, among other things, competition, brand
recognition, the ability of the acquired companies to grow and
manage growth profitably and retain their key employees; (v)
Nanox’s ability to enter into and maintain commercially reasonable
arrangements with third-party manufacturers and suppliers to
manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox
System and the proposed pay-per-scan business model; (vii) Nanox’s
expectations regarding collaborations with third-parties and their
potential benefits; and (viii) Nanox’s ability to conduct business
globally; (ix) changes in global, political, economic, business,
competitive, market and regulatory forces; and (x) risks related to
business interruptions resulting from the COVID-19 pandemic or
similar public health crises, among other things.
For a discussion of other risks and uncertainties, and other
important factors, any of which could cause Nanox’s actual results
to differ from those contained in the Forward-Looking Statements,
see the section titled “Risk Factors” in Nanox’s Annual Report on
Form 20-F for the year ended December 31, 2021, and subsequent
filings with the U.S. Securities and Exchange Commission. The
reader should not place undue reliance on any forward-looking
statements included in this press release.
Except as required by law, Nanox undertakes no obligation to
update publicly any forward-looking statements after the date of
this report to conform these statements to actual results or to
changes in the Company’s expectations.
Contacts Nanox Media Contact: Rachael
Roselli ICR Westwicke NanoxPR@icrinc.com
Investor Contact: Mike Cavanaugh ICR
Westwicke mike.cavanaugh@westwicke.com
Nano X Imaging (NASDAQ:NNOX)
Historical Stock Chart
From Apr 2024 to May 2024
Nano X Imaging (NASDAQ:NNOX)
Historical Stock Chart
From May 2023 to May 2024